Edgewise Therapeutics, Inc. EWTX
42.68 USD +3.81 (+9.81%)
Nov 6, 2026, 11:33 AM EST
38.05 Day range 43.90
16.70 52-week range 48.51
- YTD
- +71.97%
- 1 year
- +149.76%
Financial health
Altman Z-Score
21.29 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
A+4 / 5 overall
- DCF 2
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 5
- P/E 4
- P/B 3
Valuation
P/E -15.2×
FY 2019 5y median -15.2× FY 2025
P/S 0.0×
FY 2019 5y median 0.0× FY 2025
P/B 4.9×
FY 2019 5y median 2.8× FY 2025
P/FCF -17.8×
FY 2019 5y median -17.8× FY 2025
EV/EBITDA -15.1×
FY 2019 5y median -15.1× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -5.6%
FY 2019 5y median -5.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -32.1%
FY 2019 5y median -29.1% FY 2025
ROIC -36.4%
FY 2019 5y median -34.2% FY 2025
ROA -30.4%
FY 2019 5y median -27.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2025
Operating Income -20.5%
FY 2019 FY 2025
EPS (diluted) -12.4%
FY 2019 FY 2025
Free Cash Flow -30.3%
FY 2019 FY 2025
Financial Health
Current Ratio 19.9×
FY 2019 5y median 19.9× FY 2025
Quick Ratio 19.9×
FY 2019 5y median 19.9× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2019 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31